Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C12H16ClNO3 |
| Molecular Weight | 257.713 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCOC(=O)COC1=CC=C(Cl)C=C1
InChI
InChIKey=XZTYGFHCIAKPGJ-UHFFFAOYSA-N
InChI=1S/C12H16ClNO3/c1-14(2)7-8-16-12(15)9-17-11-5-3-10(13)4-6-11/h3-6H,7-9H2,1-2H3
| Molecular Formula | C12H16ClNO3 |
| Molecular Weight | 257.713 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: http://smart-drugs.net/article-lucidril.htmCurator's Comment: description was created based on several sources, including
http://toppharma.co.uk/top-pharma-product/powder-for-injection/meclofenoxate/
Sources: http://smart-drugs.net/article-lucidril.htm
Curator's Comment: description was created based on several sources, including
http://toppharma.co.uk/top-pharma-product/powder-for-injection/meclofenoxate/
Meclofenoxate (INN, BAN) (brand name Lucidril), also known as centrophenoxine, is a cholinergic nootropic used as a dietary supplement and drug in the treatment of symptoms of senile dementia and Alzheimer's disease. Meclofenoxate has been shown in studies to be effective in enhancing the memory and in improving the cognitive functions of the elderly. Some studies even suggest that Meclofenoxate has the ability to reverse the signs of brain aging. While claims about its ability as a nootropic agent have not been fully established in clinical trials, some studies do strongly suggest that it is indeed very effective in improving memory retention and recall. Meclofenoxate HCL Powder for Injection is also indicated for the following conditions: comma; skull and brain trauma; following a stroke; encephalopathy; mental disorders (in combination with psychotropic agents); mental and psychomotor retardation in children; brain intoxication; alcohol psychoses; neuritis and polyneuritis. The main mechanism of action of Meclofenoxate is generally believed to be cholinergic in nature. As an efficient transporter of DMAE, Meclofenoxate encourages the production of choline in the brain, which is then synthesized into acetylcholine. The more acetylcholine neurotransmitters in the brain, the better and more efficient the cognitive functions will be. Meclofenoxate also increases cellular membrane phospholipids
CNS Activity
Sources: http://nootropicsupplementreview.com/meclofenoxate/
Curator's Comment: Meclofenoxate increases the dimethylethanolamine or DMAE levels in the brain. DMAE is a precursor of acetylcholine, an important neurotransmitter in the brain believed to be responsible for most of the cognitive processes within it.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| A simple and sensitive HPLC method for quantification of the metabolin of meclofenoxate in human plasma. | 2010-06-03 |
|
| [Transcutaneous electrical acupoint stimulation combined with auricular acupoint sticking for treatment of primary nocturnal enuresis]. | 2010-05 |
|
| Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson's disease. | 2009-11 |
|
| Bioequivalence and pharmacokinetic comparison of a single 200-mg dose of meclofenoxate hydrochloride capsule and tablet formulations in healthy Chinese adult male volunteers: a randomized sequence, open-label, two-period crossover study. | 2008-09 |
|
| [Effects of nicotinic cholinoreceptor ligands and nootropic drugs on the spontaneous exploratory activity in a labyrinth in mice]. | 2008-07-26 |
|
| [Effects of piracetam and meclofenoxate on the brain NMDA and nicotinic receptors in mice with different exploratory efficacy in the cross maze test]. | 2008-03-28 |
|
| Behavioral alterations in rotenone model of Parkinson's disease: attenuation by co-treatment of centrophenoxine. | 2008-03-27 |
|
| Treatment of urinary incontinence after stroke in adults. | 2008-01-23 |
|
| Further evidence of centrophenoxine mediated protection in aluminium exposed rats by biochemical and light microscopy analysis. | 2007-12 |
|
| Stability-indicating electrochemical methods for the determination of meclophenoxate hydrochloride and pyritinol dihydrochloride using ion-selective membrane electrodes. | 2007-01 |
|
| Kinetic study on the degradation of meclophenoxate hydrochloride in alkaline aqueous solutions by high performance liquid chromatography. | 2007-01 |
|
| Evidence for centrophenoxine as a protective drug in aluminium induced behavioral and biochemical alteration in rat brain. | 2006-10 |
|
| Reversal of an aluminium induced alteration in redox status in different regions of rat brain by administration of centrophenoxine. | 2006-10 |
|
| Modulatory effects of centrophenoxine on different regions of ageing rat brain. | 2005-10 |
|
| Therapy of hearing disorders - conservative procedures. | 2005 |
|
| Centrophenoxine improves chronic cerebral ischemia induced cognitive deficit and neuronal degeneration in rats. | 2004-12 |
|
| Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials. | 2004-11 |
|
| Brain cholinesterases: III. Future perspectives of AD research and clinical practice. | 2004 |
|
| Effect of centrophenoxine on water-immersion restraint stress- and chemically-induced gastric ulcers in rats. | 2003 |
|
| Pharmacological interventions against aging through the cell plasma membrane: a review of the experimental results obtained in animals and humans. | 2002-04 |
|
| Cholinergic medication for neuroleptic-induced tardive dyskinesia. | 2002 |
|
| Can nootropic drugs be effective against the impact of ethanol teratogenicity on cognitive performance? | 2001-02 |
Patents
Sample Use Guides
Elderly people with significant intellectual decline may chose 3 to 6 Centrophenoxine tablets (250 mg) per day taken preferably with breakfast and lunch, in order to avoid insomnia.
For the non-elderly wishing to utilize the brain boosting benefits of Centrophenoxine, perhaps only 1 or 2 Centrophenoxine tablets (250 mg each) daily with breakfast or lunch.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/3018064
The superoxide radical scavenging ability of centrophenoxine (CPH/MECLOFENOXATE) was studied in vitro using the method of pyrogallol autoxidation, cytochrome c reduction and photoxidation of o-dianisidine in salt-free assay media and in the presence of increasing NaCl or KCl concentrations. The CPH proved to be a superoxide radical scavenger in all three systems used, however, the rate constant for this reaction was rather low (1.7 X 10(2) M-1 s-1).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:49:59 GMT 2025
by
admin
on
Mon Mar 31 17:49:59 GMT 2025
|
| Record UNII |
C76QQ2I0RG
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QN06BX01
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
||
|
WHO-ATC |
N06BX01
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
||
|
DSLD |
1889 (Number of products:4)
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
D002504
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | |||
|
MECLOFENOXATE
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | |||
|
DTXSID9046940
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | |||
|
200-116-3
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | |||
|
169411
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | |||
|
DB13758
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | |||
|
4039
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | |||
|
C174654
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | |||
|
SUB08679MIG
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | |||
|
51-68-3
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | |||
|
1651
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | |||
|
1083
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | |||
|
100000081777
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | |||
|
m7121
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | Merck Index | ||
|
C76QQ2I0RG
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | |||
|
CHEMBL64545
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | |||
|
2228
Created by
admin on Mon Mar 31 17:49:59 GMT 2025 , Edited by admin on Mon Mar 31 17:49:59 GMT 2025
|
PRIMARY | RxNorm |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |